These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23632946)

  • 1. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
    Cohen JA; Barkhof F; Comi G; Izquierdo G; Khatri B; Montalban X; Pelletier J; Eckert B; Häring DA; Francis G
    J Neurol; 2013 Aug; 260(8):2023-32. PubMed ID: 23632946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
    Barkhof F; de Jong R; Sfikas N; de Vera A; Francis G; Cohen J;
    Mult Scler; 2014 Nov; 20(13):1704-13. PubMed ID: 24812043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
    Agius M; Meng X; Chin P; Grinspan A; Hashmonay R
    CNS Neurosci Ther; 2014 May; 20(5):446-51. PubMed ID: 24684973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
    Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
    Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
    Sanford M
    Drugs; 2014 Aug; 74(12):1411-33. PubMed ID: 25063048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.
    Muris AH; Rolf L; Damoiseaux J; Koeman E; Hupperts R
    BMC Neurol; 2014 Aug; 14():164. PubMed ID: 25138918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
    Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.